Pharmacokinetic/pharmacodynamic-based decision making in the development of MK-0888, a VEGFR-2/FLT-3 kinase inhibitor
Marian Iwamoto(Merck & Co., Inc., Rahway, NJ, USA (United States)), John A. Wagner(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jennifer Talaty(Merck & Co., Inc., Rahway, NJ, USA (United States)), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Nancy Agrawal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Evan Friedman(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 0
Related Papers
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
Total Synthesis of Spirotryprostatin A, Leading to the Discovery of Some Biologically Promising Analogues
|Journal of the American Chemical Society|1999|463
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
|Proceedings of the National Academy of Sciences|1996|409
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
|PubMed|1995|385
Micro RNA 145 Targets the Insulin Receptor Substrate-1 and Inhibits the Growth of Colon Cancer Cells
|Journal of Biological Chemistry|2007|356